Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.22%
#3 Glidr Glidr +36.87%
#4 CoW Protocol CoW Protocol +34.95%
#5 Humanity Humanity +26.29%
#6 Codatta Codatta +19.83%
#7 Walrus Walrus +18.24%
#8 Enso Enso +17.51%
#9 RedStone RedStone +16.76%
#10 Collector Crypt Collector Crypt +14.50%
Coin of the day
EXOD EXOD
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Fresh Tracks Therapeutics, Inc. Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc.

FRTX
Classifica tra le azioni #36397
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused... Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.
Prezzo delle azioni
$0.94
Ultima sincronizzazione: 2025-02-28
Capitalizzazione di mercato
$2.73M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Fresh Tracks Therapeutics, Inc. (FRTX)

Categoria

Healthcare
Utile per Fresh Tracks Therapeutics, Inc. (FRTX)
Utile nel Dec 2023 TTM: $-5.89M
Secondo gli ultimi rapporti finanziari di Fresh Tracks Therapeutics, Inc., gli utili attuali della società sono $-5.89M. Nel 2022, la società ha registrato un utile di $-21.10M, un aumento rispetto a agli utili del 2021, che erano di $-39.47M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Fresh Tracks Therapeutics, Inc. dal 2000 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
2026 (TTM) $-5.89M 3.46%
2023 $-5.69M -73.02%
2022 $-21.10M -46.54%
2021 $-39.47M 88.75%
2020 $-20.91M -12.41%
2019 $-23.88M 46.90%
2018 $-16.25M 25.42%
2017 $-12.96M 44.43%
2016 $-8.97M -2.87%
2015 $-9.24M -43.98%
2014 $-16.49M -47.21%
2013 $-31.24M 36.42%
2012 $-22.90M 214.42%
2011 $-7.28M -76.03%
2010 $-30.39M 6.40%
2009 $-28.56M -22.56%
2008 $-36.88M 3.01%
2007 $-35.80M 56.49%
2006 $-22.88M 0.00%
2005 0.00 0.00%
2004 0.00 -100.00%
2003 $-26.59M -25.80%
2002 $-35.83M 0.00%
2001 0.00 0.00%
2000 0.00 0.00%
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -89,641.67%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -33,212.38%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -51,122.19%
BE